Cart
sales@molnova.com
RO6889678
CAS No. 1578153-27-1
RO6889678( RO 6889678 )
Catalog No. M12255 CAS No. 1578153-27-1
RO6889678 is a highly potent inhibitor of HBV capsid formation with attributes that are favorable for targeting the liver, whilst maintaining moderate peripheral exposure.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 161 | In Stock |
|
| 2MG | 93 | In Stock |
|
| 5MG | 131 | In Stock |
|
| 10MG | 188 | In Stock |
|
| 25MG | 269 | In Stock |
|
| 50MG | 420 | In Stock |
|
| 100MG | 618 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRO6889678
-
NoteResearch use only, not for human use.
-
Brief DescriptionRO6889678 is a highly potent inhibitor of HBV capsid formation with attributes that are favorable for targeting the liver, whilst maintaining moderate peripheral exposure.
-
DescriptionRO6889678 is a highly potent inhibitor of HBV capsid formation with attributes that are favorable for targeting the liver, whilst maintaining moderate peripheral exposure.HBV InfectionPhase 1 Discontinued.
-
In Vitro——
-
In Vivo——
-
SynonymsRO 6889678
-
PathwayMicrobiology/Virology
-
TargetHBV
-
RecptorHBV
-
Research AreaInfection
-
IndicationHBV Infection
Chemical Information
-
CAS Number1578153-27-1
-
Formula Weight494.922
-
Molecular FormulaC21H20ClFN4O5S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C([C@H]1N(CC2=C(C(OC)=O)[C@H](C3=CC=C(F)C=C3Cl)N=C(C4=NC=CS4)N2)CCOC1)O
-
Chemical Name(S)-4-(((R)-6-(2-chloro-4-fluorophenyl)-5-(methoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholine-3-carboxylic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kratochwil NA, et al. J Pharmacol Exp Ther. 2018 Feb 16. pii: jpet.117.245712.
molnova catalog
related products
-
HBV-IN-37
HBV-IN-37 is an HBV inhibitor with an EC50 value of 10 μM and can be used for hepatitis B disease-related research.
-
ccc_R08
ccc_R08 is an orally available HBV cccDNA inhibitor that reduces extracellular levels of HBV DNA, HBsAg, and HBeAg in a dose-dependent manner. ccc_R08 is investigational for use in the treatment of HBV infections. ccc_R08 has been shown to be effective in the treatment of hepatitis C virus (HCV).
-
Lagociclovir
Lagociclovir (MIV-210), a nucleoside analogue, is an antiviral compound available for the treatment of HBV82 that inhibits the replication of wild-type hepatitis B virus (HBV) in human hepatocellular carcinoma cell lines that permanently express HBV.
